MedTrace Logo

Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents

NCT00638794 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 8575

Last updated 2013-01-23

No results posted yet for this study

Summary

Prospective, multicenter, registry of at least 11,000 (and up to 15,000) consecutive patients with coronary artery disease undergoing stent-assisted percutaneous coronary intervention (PCI) using DES without major procedural complications.

Conditions

Interventions

DEVICE

Drug -Eluting Stent (Taxus™, Cypher®, Endeavor™, Xience V™)

PCI using any FDA approved drug-eluting stent; Taxus Express2 - Paclitaxel-Eluting Coronary Stent System Cypher Sirolimus-eluting coronary stent Endeavor ABT-578 Eluting Coronary Stent System Xience V Everolimus Eluting Coronary Stent System

Sponsors & Collaborators

  • Dickson Advanced Analytics Group

    collaborator UNKNOWN

  • Cardiovascular Research Foundation, New York

    lead OTHER

Principal Investigators

  • Gregg W. Stone, MD · CardioVascular Research Foundation

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2011-12-31
Completion
2013-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00638794 on ClinicalTrials.gov